CoChat

Growth Hormone Receptor Antagonists

Muller, Alex F., Kopchick, John J., Flyvbjerg, Allan, van der Lely, Aart Jan · 2004 · The Journal of Clinical Endocrinology & Metabolism
Cited by 90

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Pegvisomant is the only member of a new class of drugs that was especially designed to block the GH receptor (GHR) and, therefore, GH action. In this review we will describe the structure and function of GH and its receptor with specific relevance to the discovery and development of GHR antagonists. With respect to clinical applications, we will first discuss the role of pegvisomant in the treatment of acromegaly. Thereafter, the potential role that pegvisomant might play in the treatment and prevention of late complications of diabetes mellitus and cancer will be discussed and compared with those of somatostatin analogs in these settings. GH is secreted by the somatotrophs of the anterior pituitary gland and acts on various tissues to promote growth and influence metabolism (1, 2). GH signal transduction begins with GH binding to a GHR on the plasma membrane (3). The cocrystal structure of the GH-GHR complex indicates that GH interacts with a preformed GHR dimer. This interaction is critical for GH-induced intracellular signal transduction (4). GH has two distinct domains (sites 1 and 2) that bind to the two identical GHRs at the cell surface. After initial, high affinity binding at site I, subsequent binding at site 2 produces functional receptor dimerization (Fig. 1A). After the GH/GHR interaction, a series of intracellular signaling systems are mobilized, ultimately resulting in the activation or inactivation of genes that are responsible for GH phenotypic effects (5). In humans and most mammals, the extracellular part of the GHR can be released from the cell surface by proteolytic cleavage, resulting in the generation of a serum GH-binding protein (6).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2002-022049

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 90

Metadata

Authors
Muller, A. F., Kopchick, J. J., Flyvbjerg, A., & van der Lely, A. J.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2004-04
Volume
89
Issue
4
Pages
1503-1511
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2066190724
Cited by
90
References
1
FWCI
5.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Growth Hormone Receptor Antagonists. https://app.cochat.ai/papers/10.1210/jc.2002-022049
The paper
Muller, A. F., Kopchick, J. J., Flyvbjerg, A., & van der Lely, A. J. (2004). Growth Hormone Receptor Antagonists. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2002-022049

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.